Abstract. Angiogenesis is an essential process for tumor development and metastasis, therefore inhibition of tumor angiogenesis has become a promising strategy for anticancer treatments. Patrinia scabiosaefolia, a well-known Oriental folk medicine, has been shown to be effective in the clinical treatment of gastrointestinal cancers. However, the precise mechanism of its tumoricidal activity remains largely unknown. Using a colorectal cancer (CRC) mouse xenograft model, the human colon carcinoma cell line HT-29 and human umbilical vein endothelial cells (HUVECs), in the present study we evaluated the effects of an ethanol extract of Patrinia scabiosaefolia (EEPS) on tumor angiogenesis in vivo and in vitro, and investigated the underlying molecular mechanisms. We found that EEPS treatment significantly reduced the tumor volume in CRC mice and decreased the intratumoral microvessel density in tumor tissues. In addition, EEPS inhibited several key processes of angiogenesis, including the proliferation, migration and tube formation of HUVECs. Moreover, EEPS treatment suppressed the expression of VEGF-A in CRC tumors and HT-29 cells. Collectively, our data suggest that Patrinia scabiosaefolia inhibits CRC growth likely via suppression of tumor angiogenesis.
Introduction
Drug resistance and toxicity to normal cells limit the effectiveness of currently used cancer chemotherapies (1) (2) (3) , increasing the necessity for the development of new antitumor agents. Natural products, including traditional Chinese medicine (TCM), has recently received great interest since these agents have relatively few side-effects and have been used as important alternative cancer remedies for many years (4, 5) . Patrinia scabiosaefolia is a perennial plant natively distributed in Eastern Asia. As a well-known Oriental folk medicine, it has long been used in China for the treatment of edema, appendicitis, endometritis and other inflammatory illnesses (6) . Patrinia scabiosaefolia is also used as an important component in several TCM formulas to clinically treat cancers (7, 8) .
However, the precise mechanism of its antitumor activity remains largely unknown.
Angiogenesis is a physiological process involving the growth of new blood vessels from the pre-existing vasculature. Although angiogenesis plays an essential role in a wide range of physiological processes such as wound healing, reproduction and embryonic development, deregulation of this vital biological process is strongly associated with cancer progression (9) (10) (11) (12) (13) . In the initial stage, tumor cells obtain oxygen and nutrients from nearby blood vessels by simple passive diffusion. However, when a tumor grows to reach a certain size, >2 mm 3 , oxygen delivery by diffusion is no longer sufficient, causing tumor cells to induce the sprouting of new blood vessels from pre-existing vasculature, creating a blood supply system within the tumor that is essential for continue growth of the tumor as well as providing an avenue for hematogenous metastasis (14) (15) (16) (17) . Induction of angiogenesis is mediated by a variety of molecules released by tumor cells (18) (19) (20) , including vascular endothelial growth factor A (VEGF-A) which is considered as one of the strongest stimulators of angiogenesis (21) (22) (23) . VEGF-A is commonly overexpressed in many types of human cancer, and is correlated with tumor progression, invasion and metastasis, and poorer survival and prognosis in patients (24) (25) (26) (27) . VEGF-A exerts its biologic effect primarily through interaction with specific receptors present on the surface of vascular endothelial cells (ECs), which in turn triggers a tyrosine kinase signaling cascade, inducing EC proliferation, migration, survival, sprouting and eventually tube formation (21, 24, 27, 28) . Due to the key role of angiogenesis in the progression of solid tumors, inhibition of tumor angiogenesis has become a major focus of anticancer drug development.
To elucidate the mechanism of the tumorcidal activity of Patrinia scabiosaefolia, using a colorectal cancer (CRC) mouse xenograft model, the human colon carcinoma cell line HT-29 and human umbilical vein endothelial cells (HUVECs), in this study we evaluated its effect on tumor angiogenesis in vivo and in vitro, and investigated the underlying molecular mechanisms. Preparation of ethanol extract from Patrinia scabiosaefolia. EEPS was prepared as described previously (8) . For animal experiments, EEPS powder was dissolved in saline to a working concentration of 250 mg/ml. In cell-based experiments, EEPS powder was dissolved in 50% DMSO to a stock concentration of 250 mg/ml and the working concentrations of EEPS were made by diluting the stock solution in the culture medium. The final concentration of DMSO in the medium for all cell experiments was <0.5%.
Materials and methods

Materials
Cell culture. Human colon carcinoma HT-29 cells and
HUVECs were obtained from the Cell Bank of the Chinese Academy of Science (Shanghai, China). HUVECs or HT-29 cells were grown in RPMI-1640 or DMEM, respectively. RPMI-1640 and DMEM were supplemented with 10% (v/v) FBS, and 100 U/ml penicillin and 100 µg/ml streptomycin. Cells were cultured at 37˚C humidified incubator with 5% CO 2 .
Animals. Male BALB/c athymic (nude) mice (with an initial body weight of 20-22 g) were obtained from the Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China) and housed under pathogen-free conditions with controlled temperature (22˚C), humidity and a 12-h light/dark cycle. Food and water were given ad libitum throughout the experiment. All animal treatments were strictly in accordance with international ethical guidelines and the National Institutes of Health Guide concerning the Care and Use of Laboratory Animals, and the experiments were approved by the Institutional Animal Care and Use Committee of Fujian University of Traditional Chinese Medicine.
In vivo tumor xenograft study. HT-29 cells (1.5x10 6 ) mixed with Matrigel (1:1) were subcutaneously injected into the right flank of the mice to initiate tumor growth. After 5 days of xenograft implantation, mice were randomly divided into 2 groups (n=6) and given intragastric administration with 1.93 g/kg/day of EEPS or saline daily, 5 days a week for 21 days. Tumor size was determined by measuring the major (L) and minor (W) diameter with a caliper. The tumor volume was calculated according to the following formula: tumor volume = π/6 x L x W 2 .
Immunohistochemical staining. After being fixed with 10% formaldehyde for 12 h, tumor samples were processed conventionally for paraffin-embedded tumor slides. The slides were subjected to antigen retrieval, and the endogenous peroxidase activity was quenched with hydrogen peroxide. After blocking non-specific proteins with normal serum in phosphate-buffered saline (PBS) (0.1% Tween-20), slides were incubated with rabbit polyclonal antibodies against CD31 and VEGF-A (1:200 dilution). After washing with PBS, slides were incubated with a biotinylated secondary antibody followed by conjugated horseradish peroxidase (HRP)-labeled streptavidin (Dako), and then washed with PBS. The slides were then incubated with diaminobenzidine (DAB) (Sigma) as the chromogen, followed by counterstaining with diluted Harris' hematoxylin (Sigma). After staining, 5 high-power fields (x400) were randomly selected in each slide, and the average proportion of positive cells in each field was counted using a true color multi-functional cell image analysis management system (Image-Pro Plus; Media Cybernetics, Rockville, MD, USA).
To rule out any nonspecific staining, PBS was used to replace the primary antibody as a negative control.
Evaluation of cell viability by MTT assay. Viability of HUVECS was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay. HUVECs were seeded into 96-well plates at a density of 1x10 4 cells/well in 0.1 ml medium. The cells were treated with various concentrations of EEPS for 24, 48 and 72 h respectively. At the end of the treatment, 100 µl MTT (0.5 mg/ml in PBS) was added to each well, and the samples were incubated for an additional 4 h at 37˚C. The purple-blue MTT formazan precipitate was dissolved in 100 µl DMSO. The absorbance was measured at 570 nm using an ELISA reader (BioTek, Model ELX800; BioTek Instruments, Inc., Winooski, VT, USA).
Migration assay of HUVECs. Migration of HUVECs was performed by the wound healing method. HUVECs were seeded into 12-well plates at a density of 2x10 5 cells/well in 1 ml medium. After 24 h of incubation, cells were scraped away vertically in each well using a P100 pipette tip. Three randomly selected views along the scraped line were photographed for each well using a phase-contrast inverted microscope at a magnification of x100. Cells were then treated with the indicated concentrations of EEPS for 24 h, and another set of images was captured using the same method. A reduction in the scraped area indicated migratory capability.
Tube formation assay of HUVECs. The tube formation of HUVECs was examined using the ECMatrix assay kit (Millipore), following the manufacturer's instructions. Briefly, confluent HUVECs were harvested and diluted (1x10 4 cells) in 50 µl of medium, containing indicated concentrations of EEPS. The harvested cells were then seeded into 1:1 ECMatrix gel (v/v)-coated 96-well plates and incubated for 9 h at 37˚C. The network-like structures were examined using a phase-contrast inverted microscope. The images were captured at a magnification of x100. The level of tube formation was quantified by calculating the length of tubes in 3 randomly chosen fields from each well.
Measurement of VEGF-A secretion in HT-29 cells by ELISA.
HT-29 cells were seeded into 6-well plates at a density of 2x10 5 cells/well in 2 ml medium and treated with the indicated concentrations of EEPS for 24 h. The level of VEGF-A in the media was measured using an ELISA kit (XiTang Biological Technology Ltd., Shanghai, China) according to the manufacturer's instructions. The concentration of VEGF-A was determined by comparison to serial dilutions of a purified standard of VEGF-A.
RT-PCR analysis. Total RNA was isolated from tumor tissues or HT-29 cells with TRIzol reagent. Oligo(dT)-primed RNA (1 µg) was reverse-transcribed with SuperScript II reverse transcriptase (Promega Corporation) according to the manufacturer's instructions. The obtained cDNA was used to determine the mRNA amount of VEGF-A by PCR with Taq DNA polymerase (Fermentas). GAPDH was used as an internal control.
Statistical analysis. Data are presented as means ± SD for the indicated number of independently performed experiments and were analyzed using the SPSS Package for Windows (version 16.0). Statistical analysis of the data was performed with the Student's t-test and ANOVA. Differences with P<0.05 were considered to be statistically significant.
Results and Discussion
EEPS inhibits tumor growth in colorectal cancer (CRC) xenograft mice.
We evaluated the tumor growth in CRC xenograft mice by measuring the tumor volume. Data in Fig. 1 indicate that EEPS treatment significantly suppressed tumor growth, as compared with the control group. The final tumor volume/mouse in the control and the EEPS-treated group was 1.20±0.31 and 0.65±0.15 cm 3 , respectively (P<0.05), suggesting that EEPS was effective in the treatment of colorectal cancer.
EEPS displays anti-angiogenic activity in CRC xenograft mouse tumors and in human umbilical vein endothelial cells.
Angiogenesis plays an important role in the progression and metastasis of cancer, which thus has become an attractive target for anticancer therapy. The expression of endothelial cell-specific marker CD31 in CRC tumor tissues was determined by immunohistochemical staining (IHS) to evaluate the effect of EEPS on intratumoral microvessel density (MVD), an indicator of new vessel growth. As shown in Fig. 2 , the percentage of CD31-positive cells in the EEPS-treated mouse tumors was significantly reduced (P<0.05), demonstrating the in vivo anti-angiogenic activity of EEPS.
Angiogenesis typically consists of several features, including proliferation, migration and eventually the capillary tube formation of endothelial cells (ECs). To further evaluate the anti-angiogenic effect of EEPS we modeled each of these processes with HUVECs in vitro. As shown in Fig. 3 , EEPS treatment dose-and time-dependently decreased the proliferation (viability) of HUVECs (P<0.05, compared to untreated control cells). Moreover, EEPS treatment inhibited HUVEC migration after monolayer wounding (Fig. 4) . Furthermore, we examined the effect of EEPS on capillary tube formation of HUVECs using an extracellular matrix. As shown in Fig. 5 , untreated HUVECs formed elongated tube-like structures; which, however, was profoundly inhibited by EEPS treatment. Taken together, it is suggested that the antitumor angiogenesis activity of EEPS could have contributed to its inhibitory effect on colorectal tumor growth.
EEPS decreases VEGF-A expression in CRC xenograft mouse tumors and human colon carcinoma HT-29 cells.
The process of tumor angiogenesis is tightly regulated by a variety of molecules released by tumor cells. Vascular endothelial growth factor A (VEGF-A) is considered as one of the most potent angiogenic stimulators. Overexpression of VEGF-A is found in numerous types of cancer and commonly suggests poor prognosis. VEGF-A functions primarily via a paracrine pathway, binding to its specific receptors located on vascular ECs after secretion from tumor cells, leading to a series of angiogenic processes. To further investigate the mechanism of the anti-angiogenic activity of EEPS, we examined its effect on the expression of VEGF-A. As shown in Fig. 6 , EEPS treatment obviously decreased the mRNA and protein expression levels of VEGF-A both in CRC tumor tissues and in HT-29 cells (P<0.01).
In conclusion, here for the first time we demonstrated that Patrinia scabiosaefolia inhibits colorectal cancer growth via inhibition of tumor angiogenesis, which may in part explain its anticancer activity.
